Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The ...

Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Receipts ("ADRs") of GSK plc (NYSE: GSK) between February 5, 2020 and August 14, 2022, both dates inclusive ...

Hedge fund Citadel has made a 305 million pound ($384.5 million) bet against drugmaker GSK , the Financial Times reported on ...

GSK launched a rare £2bn share buyback and raised its growth targets on the back of strong sales of speciality medicines, ...

GSK launched a 2 billion pounds ($2.5 billion) share buyback on Wednesday and lifted its long-term sales target to nearly $50 ...

Despite significant dips in its vaccines sales, the British pharma narrowly beat consensus estimates for Q4 2024 and raised ...

GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Hedge fund Citadel has made a £305mn bet against drugmaker GSK, the biggest short position against the company in more than a decade.

GSK was able to offset the decline thanks to a better-than-expected performance for its cancer medicines and HIV therapeutics sold by majority-owned joint venture ViiV Healthcare, which helped group ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from developing. The partnership intends to create a vaccine or vaccines which target ...

The company has placed a strong emphasis on expanding its cancer drug portfolio and specialty medicines. However, GSK's latest financial report comes amid a barrage of lawsuits, including a major ...